Clinical Trials Directory

Trials / Completed

CompletedNCT02579421

Hormones and Reduction in Co-users of Marijuana and Nicotine

Sex Differences and Progesterone: Association With Impulsivity and Marijuana Reduction in Co-Users of Marijuana and Nicotine Cigarettes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
58 (actual)
Sponsor
University of Minnesota · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to examine the role of progesterone (a naturally occurring hormone found in both men and women) on reducing marijuana use. The investigators will see if progesterone effects impulsivity, withdrawal, mood and stress during marijuana cessation.

Detailed description

This double-blind, randomized pilot clinical trial will prescreen an estimated 250 potential subjects, consent and further evaluate approximately 100 potential subjects, and ultimately enroll 70 subjects to ensure 40 subjects will provide a primary marijuana reduction outcome measure at four weeks post quit date. Subjects will be stratified by sex then randomized to one of two treatment groups (n=20 per drug group, 50% female): progesterone (PRO; 200mg 2x/day) or Placebo (PBO). Telephone screening and visit invitation (20 minutes) leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion (two visits, two hours each), then randomization and medication start (7 days), then stable medication (28 days) with medication reduction and final evaluation (7 days).

Conditions

Interventions

TypeNameDescription
DRUGProgesteronegeneric progesterone
DRUGplaceboplacebo

Timeline

Start date
2015-11-01
Primary completion
2017-07-27
Completion
2017-07-27
First posted
2015-10-19
Last updated
2020-06-26
Results posted
2019-07-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02579421. Inclusion in this directory is not an endorsement.